Novel artemisinin-glycolipid hybrids were directly synthesized from 12b b (C-C)-type deoxoartemisinin and glycolipid and exhibited exceptional in vitro anticancer activity, particularly against the oral carcinoma cancer cell lines, respectively. The artemisinin-glycolipid hybrids, with effective concentrations under 20 m mM, demonstrated better anticancer activity than either artemisinin or glycolipid alone and showed five times more anti-oral cancer activity than either cisplatin or paclitaxel.
Regular Article Artemisinin (1) (Fig. 1) , also known as qinghaosu, is a natural sesquiterpene trioxane isolated from Artemisia annua L. 1) Artemisinin and its derivatives have been used clinically to treat drug-resistant malaria. [2] [3] [4] [5] [6] The pharmacology and pharmacokinetics of artemisinin and its derivatives are well studied. [7] [8] [9] [10] [11] [12] Artemisinin derivatives have also been reported to have antiangiogenic activity. [13] [14] [15] [16] [17] [18] [19] [20] We recently reported that 12b(C-C)-type artemisinin show strong anti-angiogenic activity. In fact, they are comparable as potent as fumagillin and thalidomide, known antiangiogenic agents. 17) As we have described previously, 17, 18, 21, 22) a variety of researchers have reported on the potential antitumor properties of artemisinin and its derivatives. [23] [24] [25] [26] [27] [28] We have previously demonstrated that 12b(C-C)-type amide derivatives of deoxoartemisinin exhibit higher in vitro anticancer activity 18) along with 20 times more acid stability than 12b(C-O)-type derivatives of artemisinin. 29) The glycolipid daumone (2) (Fig. 1) , a pheromone isolated from Caenorhabditis elegans, was identified by our laboratory and its total synthesis was previously presented. 30) Daumone signals C. elegans to enter the dauer stage, an enduring and non-aging stage of the nematode life cycle with distinctive adaptive features and extended life. 30) Although some studies have suggested the possibility of using glycolipids as anticancer chemotherapeutic agents, the relatively weak activity of this class of compounds has generally discouraged further investigation. [31] [32] [33] [34] [35] Recently, glycolipids fractionated from spinach have been shown to inhibit the activities of replicative DNA polymerase (pols), mitochondrial pol, 36) and glycosphingolipids found in invertebrates not having sialic acid suppressed cell proliferation, an effect associated with suppression of the activation of focal adhesion kinase (FAK), extracellular signal-regulated kinase (Erk), and AKT in melanoma B16F10 cells. 37) We previously reported a versatile synthesis of novel glycolipid derivatives through stereospecific a-glycosylation to afford di-and tri-rhamnoside daumone derivatives, most of which possessed potent anticancer activity against human cancer cell lines with effective concentrations in the nanomolar range, which is comparable to that of doxorubicin. 38) In order to improve anticancer activity, treatment using hybrids drugs, an approach that incorporates two drugs into a single molecule, has been developed. 39) The use of hybrid drugs can impact multiple targets simultaneously. Although gefitinib originally developed as anti-lung cancer drug has been later reported to be cytotoxic against oral cell line (HSC-2), 40) no anti-oral cancer agent has been reported in the literature to date.
In this study we report on the practical synthesis and the potent in vitro anti-oral cancer activity of derivatives of 12b(C-C)-type deoxoartemisinin, glycolipids, and novel artemisinin-glycolipid hybrids.
Results and Discussion
As outlined in Chart 1, compound 6 22) was obtained through 5 consecutive reactions from artemisinc acid (3) 41) via 12-allylic deoxoartemisinin (4) and 12-(3-hydroxypropyl)deoxoartemisinin (5) . 41, 42) New amide derivatives 7 and 8 were prepared by reacting compound 6 with 3-aminoquinoline or piperazine in the presence of 1-hydroxybenzotriozole (HOBt) or 4-dimethylaminopyridine (DMAP) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) as coupling agents with the previously described method 18) to give 89% and 52% yields, respectively (Chart 1).
During the stereospecific total synthesis 30) of daumone (2) from L-rhamnose in ten steps, the versatile intermediate 9 was briefly used for the preparation of compounds 10, 38) 12, and daumone 2 by the known procedure 30) as shown in Chart 2.
The controlled ozonolysis of compound 9 using ozone in methylene chloride and subsequent reduction with NaBH 4 provided compound 11 in one step with 66% yield.
Artemisinin-glycolipid hybrids 14, 15 and 16 were prepared by following the procedures (Chart 3).
Oxidation of the double bond of the intermediate 4 gave carboxymethyldeoxoartemisinin 13a by the known procedure. 41) The coupling between compound 13a and compound 10 using EDC and DMAP gave hybrids 14 and 15 with 31% and 32% yields, respectively. The hybrid 16 was prepared in a fashion similar to the above coupling step from 12-hydroxyethyldeoxoartemisinin, 13b 43) obtained from compound 4. In order to determine the in vitro anticancer activities of artemisinin (1), daumone (2), compounds 7, 8, 11, 12, and hybrids 14, 15, and 16, we tested the cell proliferation inhibitory activity of these derivatives against the cancer cell lines, MDA-MB-231, A549, HSC-2 and Ca.9-22 using the 3-
The results of this analysis are summarized in Table 1 . The standard drugs used for comparison were cisplatin, paclitaxel and gefitinib as positive controls. We found that the inhibitory effects of all compounds (at micromolar concentrations) differed according to the type of cancer cell line.
In our conditions, artemisinin and daumone, as well as cisplatin and paclitaxel, failed to show notable activities at concentrations under 100 mM. For the breast cancer (MCF-7) cell line, all tested molecules had IC 50 values at 100 mM. In lung cancer (A549) cell lines, only the artemisinin-glycolipid hy-brid 15 showed three times more potent anticancer activity than those of the references 44, 45) at a concentration of 29.7 mM. For breast cancer (MDA-MB-231) cell lines, compounds 8, 11, 12, 14 and 15 showed one to two times more potent anticancer activity compared with cisplatin 46) or paclitaxel. 47) For the oral squamous carcinoma cells lines (HSC-2 and Ca.9-22), artemisinin derivatives 7 and 8 and glycolipid derivatives 11 and 12 generally possessed more potent anticancer activities at up to three times that of the reference drugs. However, artemisinin derivatives showed more potent activity than glycolipid derivatives. Particularly, the hybrids 14 and 15, with IC 50 values under 20 mM, showed five to six times more potent anti-oral cancer activity than either cisplatin or paclitaxel and comparable activity to that of gefitinib. In comparison, the 12b(C-C)-type dimer artemisinin derivative (8) generally showed better anticancer activity than the 12b(C-C)-type monomer (7). Moreover, 12b(C-O)-type derivatives exhibited, as shown in artemisinin, weaker activities than 12b(C-C)-type derivatives. These results are in accordance with previous observations. 17) In the case of glycolipid derivatives, the benzoyl protected glycolipids 11 and 12 showed better activities than the non-protected glycolipid daumone (2) . This trend was also observed with the artemisinin-glycolipid hybrids. Interestingly, hybrid 16 showed lower anticancer activity, suggesting the importance of regiospecificity. The artemisinin derivative should be connected with one of the hydroxy groups of the tetrahydropyran ring of glycolipid. As expected, the anticancer activities of hybrids 14 and 15 were much more potent than single monomers of artemisinin or glycolipid, respectively. In a mode of proposed action, selective approach of the hybrids with proper combination of lipophilicity and hydrophilicity to the cancer cell membrane may enhance anticancer activity arisen by homolytic cleavage of internal peroxide of artemisinin.
Conclusion
In summary, two new 12b(C-C)-type artemisinin amide derivatives were synthesized and they showed potent antioral cancer activity. Hybrids of 12b(C-C)-types of artemisinin and glycolipid were synthesized in one-step reactions and these hybrids showed exceptional anti-oral cancer activity. It is also noteworthy that the hybrid compounds generally showed drastic increases in anticancer activity in comparison with the non-coupled molecules artemisinin (1) or daumone (2) alone. The artemisinin-glycolipid hybrids deserve further evaluation as possible anti-oral cancer drug candidates.
Experimental
Chemistry Commercial reagents were obtained from commercial suppliers and used as received. All solvents were purchased in septum sealed bottles stored under an inert atmosphere. All reactions were sealed with septa through which an argon atmosphere was introduced unless otherwise noted. Liquid reagents and solvents were transferred under a positive pressure of argon via syringe. Reactions were conducted in round-bottomed flasks containing Teflon-coated magnetic stir bars. Reactions were monitored by thin layer chromatography (TLC) on precoated TLC glass plates (silica gel 60 F254, 250 mm thickness). Visualization of the developed TLC chromatogram was performed by fluorescence quenching. Flash chromatography was performed on an automated purification system using prepacked silica gel columns.
1 H-NMR were recorded on NMR spectra (250 MHz) were obtained on Bruker AC250 spectrometer using Me 4 Si as an internal standard and 13 C-NMR spectra (100 MHz) were measured on the same instrument; chemical shifts (d) are reported relative to residual protio solvent signals. Data for NMR spectra are reported as follows: chemical shift (d ppm), multiplicity (sϭsinglet, br sϭbroad singlet, dϭdoublet, tϭtriplet, qϭquartet, ddϭdoublet of doublets, mϭmultiplet), coupling constant (Hz), integration.
( 3R,5aS,6R,8aS,9R,10R,12R,12aR) -[2 -(3-Amidequinoline)]-decahy- dro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10 (6R)-6-Hydroxyheptyl-2,4-O-benzoyl-3,6-dideoxy-L-rhamnoside (11) To the solution of benzoyl-3,6-dideoxy-L-rhamnosepyranosyl)heptene 9 (200 mg, 0.42 mmol) in methylene chloride(20 ml), O 3 was added through bubbling at Ϫ78°C for 3 min. After methylene chloride was removed in vacuo, the reaction mixtures were dissolved in ethanol (30 ml) at 0°C. NaBH 4 (195 mg, 5.14 mmol) was in several times added to the solution. After 16 h stirring, the reaction was quenched by addition with distilled water, extracted with EtOAc(150 mlϫ3). Washing with sat. brine, drying with anh. MgSO 4 , and concentration in vacuo afforded a solid. Purification with flash column chromatography gave compound 11, a colorless solid (126 mg, 66%). 12H-pyrano[4,3-j]-1,2-benzodioxepin-10-acetate]-(1R)-1-methyl-6-hepten-1-yl 3,6-Dideoxy-a a-L-arabino-hexopyranoside (14) A stirred solution of carboxymethyldeoxoartemisinin (15.0 mg, 0.046 mmol), EDC (88.0 mg, 0.46 mmol) and DMAP (56.1 mg, 0.46 mmol) in DMF (2 ml) was combined with olefinic daumone 10 (15.0 mg, 0.046 mmol) at room temperature during 12 h. The reaction mixture was quenched with slow addition of saturated citric acid (2 ml), extracted with ethyl acetate (3ϫ5 ml) and washed with NaHCO 3 (5 ml) and brine (5 ml In Vitro Antitumor Assay The in vitro cytotoxicity of artemisinin, daumone and their synthesized hybrids to the human cancer cells was defined by the microculture tetrazolium assay as described by Carmichel et al. 48) Paclitaxel and cisplatin were used as the reference substances, exhibiting the activity with an IC 50 (mM) as shown in Table 1 toward human cell lines.
